Huang K, Hu JH, Wang HF, He WP, Chen J, Duan XZ, Zhang AM, Liu XY.
World J Gastroenterol. 2011 Aug 7;17(29):3448-52. doi: 10.3748/wjg.v17.i29.3448.
Liver Failure Treatment and Research Center, 302 Military Hospital, Peking University Health Science Center, Beijing 100191, China.
AIM:
To investigate the survival rates and prognostic factors in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF).
METHODS:
Clinical data in hospitalized patients with HBV-ACLF admitted from 2006 to 2009 were retrospectively analyzed. Their general conditions and survival were analyzed by survival analysis and Cox regression analysis.
RESULTS:
A total of 190 patients were included in this study. The overall 1-year survival rate was 57.6%. Patients not treated with antiviral drugs had a significantly higher mortality [relative risk (RR) = 0.609, P = 0.014]. The highest risk of death in patients with ACLF was associated with hepatorenal syndrome (HRS) (RR = 2.084, P =0.026), while other significant factors were electrolyte disturbances (RR = 2.062, P = 0.010), and hepatic encephalopathy (HE) (RR = 1.879, P < 0.001).
CONCLUSIONS:
Antiviral therapy has a strong effect on the prognosis of the patients with HBV-ACLF by improving their 1-year survival rate. HRS, electrolyte disturbances, and HE also affect patient survival.
KEYWORDS:
Acute-on-chronic liver failure, Antiviral therapy, Hepatitis B virus, Nucleosides, Survival analysis
